HER2-low breast cancer: Trastuzumab-Deruxtecan improves PFS without...

HER2-low breast cancer: Trastuzumab-Deruxtecan improves PFS without…

0 Comments

medicine

Thursday, June 6, 2024

Chicago Trastuzumab-Deruxtecan delays cancer growth in patients with metastatic, hormone receptor-positive, HER2-low or HER2-ultralow breast cancer that has progressed after endocrine therapy (ET). This is shown by the results of the DESTINY-Breast06 study presented at the 2024 (ASCO) Annual Meeting (Abstract LBA1000). These results could also lead to a shift in the classification and treatment of metastatic breast cancer…

#HER2low #breast #cancer #TrastuzumabDeruxtecan #improves #PFS #without..

Leave a Reply

Related Posts